Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma
A phase 2 trial of Vusolimogene oderparepvec and Pembrolizumab in Angiosarcoma, run by Varun Monga, MBBS, now recruiting.
Overview
Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma is a phase 2 interventional study registered as NCT06898970 by Varun Monga, MBBS, with 18 participants planned, started 2026-01-09 and due to reach its primary completion in 2029-10-31. Interventions recorded: Vusolimogene Oderparepvec (VO), Pembrolizumab. Conditions recorded: Angiosarcoma, Angiosarcoma, Adult.
Linked to the drug Vusolimogene oderparepvec because the registry names it among its interventions and Angiosarcoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialVO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Shares Vusolimogene oderparepvec, Pembrolizumab and the tag pipeline.
- TrialIsunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)
Shares Pembrolizumab and the tag pipeline.
- TrialLess Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
Shares Pembrolizumab and the tag pipeline.
- TrialFirst in Human Study of T3P-Y058-739 (T3P)
Shares Pembrolizumab and the tag pipeline.
- TrialN-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors
Shares Pembrolizumab and the tag pipeline.
- TrialA Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme
Shares Pembrolizumab and the tag pipeline.
- TrialDepsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
Shares Angiosarcoma and the tag pipeline.
- TrialA Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
Shares Pembrolizumab and the tag pipeline.